ArticleMolecular pharmaceutics2026
Application of Allometric Scaling and Translational Modeling to Predict Human Pharmacokinetics of mRNA-Encoded Antibodies.
Article in Molecular pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Messenger RNA (mRNA)-lipid nanoparticle (mRNA-LNP) platforms enable the in vivo expression of almost any therapeutic protein, offering unprecedented flexibility for clinical translation. However, for these rapidly deployable therapies, predicting the first-in-human (FIH) dose remains a key challenge. We developed an allometric scaling framework for human pharmacokinetic (PK) prediction of antibodies expressed from intravenously administered mRNA-LNPs, leveraging preclinical and clinical data for BNT141 (encoding RiboMab01, a full IgG1) and BNT142 (encoding RiboMab02.1, a bispecific Fab-scFv-based T-cell engager). The dose-normalized Cmax (DCmax) and dose-normalized AUC (DAUC) of translated antibodies across multiple species could be described by the allometric approach, with the estimated exponents ranging from -1.29 to -1.42 for BNT141 and BNT142. We also determined generalized single-species allometric scaling exponents of -1.26 from mice and -0.75 from nonhuman primate (NHP), respectively, that enabled the human predictions of translated antibodies exposure approximately 4-fold (mice) and within 2-fold (NHP). A mechanistic cross-species translational model was further developed that integrated mRNA-specific elimination and translation efficiency parameters to characterize the exposure of the translated antibodies from mRNA-based therapeutics. The translational model could predict the human PK exposure of translated antibodies within 1.33-fold for BNT141 and BNT142 via single-species scaling from NHP parameters as well as capturing the concentration-time profiles with reasonably high fidelity. Validation with publicly available mRNA-1944 (encoding CHKV-24, full IgG1) data confirmed both the allometric scaling and translational modeling methods' robustness when scaling from NHP data. Taken together, these results support a generalized cross-species PK relationship that is independent of the molecular characteristics of the translated antibodies or antibody-like protein products. This integrated scaling and modeling framework offers a generalizable solution for accelerating FIH dose selection of mRNA-encoded therapeutic antibodies and is adaptable to other recombinant proteins of interest.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.